Mercedes Torres-Ingelmo

Barcelona, CT 08036, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Correction: Pérez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.

Correction: Pérez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.

Journal: Biomedicines

Published: July 03, 2026

Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck.

Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck.

Journal: Cancer cytopathology

Published: March 29, 2026

Role of Bladder EpiCheck® in Bladder cancer: from primary diagnosis to surveillance.

Role of Bladder EpiCheck® in Bladder cancer: from primary diagnosis to surveillance.

Journal: Journal of translational medicine

Published: March 12, 2026

Machine Learning-Based Gene Expression Analysis to Identify Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.

Machine Learning-Based Gene Expression Analysis to Identify Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.

Journal: Cancers

Published: July 02, 2025

Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.

Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.

Journal: BJU international

Published: March 06, 2025

Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer.

Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer.

Journal: Biomedicines

Published: February 17, 2025

cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer.

cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer.

Journal: EJNMMI research

Published: August 28, 2024

Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy.

Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy.

Journal: Diagnostics (Basel, Switzerland)

Published: August 27, 2024

Prognostic Value of Liquid-Biopsy-Based Biomarkers in Upper Tract Urothelial Carcinoma.

Prognostic Value of Liquid-Biopsy-Based Biomarkers in Upper Tract Urothelial Carcinoma.

Journal: International journal of molecular sciences

Published: February 27, 2024

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.

Journal: International journal of molecular sciences

Published: November 05, 2023

Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.

Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.

Journal: Frontiers in oncology

Published: August 01, 2023

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.

Journal: International journal of molecular sciences

Published: August 31, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026